The U.S. Food and Drug Administration has issued warnings to more than 2,200 pharmaceutical companies, academic institutions, and researchers for failing to report clinical trial results as required by federal law, according to regulatory documents obtained by STAT. The agency indicated non-compliant parties could face civil monetary penalties of up to $12,103 per day for ongoing violations.
The enforcement push targets sponsors of trials completed between 2017-2022 that neglected to submit results to ClinicalTrials.gov within one year of completion. FDA officials confirmed this represents the agency’s largest coordinated action since reporting requirements were strengthened under 2017’s FDA Reauthorization Act.
‘This isn’t about paperwork – it’s about patients and practitioners having complete information to make medical decisions,’ said a senior FDA official speaking on background. The agency’s analysis suggests approximately 15% of applicable trials remain unreported beyond the statutory deadline.
Medical ethicists have long criticized gaps in clinical trial transparency. ‘Selective reporting distorts the evidence base,’ noted Dr. Harlan Krumholz, a Yale cardiologist who studies research integrity. ‘When negative results go unpublished, it creates false confidence in treatments.’
The FDA’s action coincides with growing scrutiny of pharmaceutical research practices. Analysts suggest the Novo Nordisk-OpenAI partnership mentioned in STAT’s report may represent industry efforts to automate compliance through AI-driven data tracking.
Legal experts warn enforcement could prove challenging. ‘Many recipients are small academic centers without dedicated compliance staff,’ said Georgetown University law professor Patricia Zettler. The FDA has not disclosed whether it will pursue fines immediately or establish a grace period for remediation.